Access cutting-edge immune thrombocytopenia treatment through this clinical trial at a research site in Stanford. Study-provided care at no cost to qualified participants.
Access immune thrombocytopenia specialists in Stanford at no cost
This study follows strict safety protocols and ethical guidelines
All study-related immune thrombocytopenia treatment provided free
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The
Sponsor: Eli Lilly and Company
Check if you qualify for this immune thrombocytopenia clinical trial in Stanford, CA
If you're searching for immune thrombocytopenia treatment options in Stanford, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Stanford research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.